Mineralys Therapeutics Inc
NASDAQ:MLYS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.76
47.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
M
|
Mineralys Therapeutics Inc
NASDAQ:MLYS
|
2.6B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
40.7B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.3B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Mineralys Therapeutics Inc
Glance View
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).